Design Therapeutics (DSGN) Shares Outstanding (Weighted Average) (2020 - 2026)

Design Therapeutics has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $61.4 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $61.4 million, up 8.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.4 million (up 8.24% YoY), and the FY2025 annual result was $57.3 million, up 1.31% from the prior year.
• Shares Outstanding (Weighted Average) came in at $61.4 million for Q1 2026 at Design Therapeutics, up from $57.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $61.4 million in Q1 2026 to a low of $55.5 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $56.5 million (2024), against an average of $56.6 million.
• Across the five-year window, Shares Outstanding (Weighted Average) jumped 214.84% in 2022 and increased 0.48% in 2025, its largest moves.
• Design Therapeutics' Shares Outstanding (Weighted Average) stood at $55.7 million in 2022, then climbed by 0.5% to $56.0 million in 2023, then increased by 1.08% to $56.6 million in 2024, then increased by 1.31% to $57.3 million in 2025, then advanced by 7.16% to $61.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $61.4 million (Q1 2026), $57.3 million (Q4 2025), and $57.0 million (Q3 2025), per Business Quant data.